





CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS :

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI, SOUTH DELHI 110030

DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar,

PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. VISWESWARA PRABHU PATIENT ID: VISWM1101924126

ACCESSION NO: **4126WA003967** AGE: 31 Years SEX: Male ABHA NO:

RECEIVED: 11/01/2023 08:42 11/01/2023 17:18 DRAWN: REPORTED:

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Results **Biological Reference Interval Units Preliminary**

MEDIWHEEL HEALTH CHEKUP BELOW 40(M)TMT

OPTHAL

TEST COMPLETED **OPTHAL**











CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS :

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI,

SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS

DDRC SRL Tower, G-131, Panampilly Nagar,

PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. VISWESWARA PRABHU PATIENT ID: VISWM1101924126

ACCESSION NO: 4126WA003967 AGE: 31 Years SEX: Male ABHA NO:

RECEIVED: 11/01/2023 08:42 DRAWN: REPORTED: 11/01/2023 17:18

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Results Units **Preliminary**

MEDIWHEEL HEALTH CHEKUP BELOW 40(M)TMT

BUN/CREAT RATIO

6 **BUN/CREAT RATIO**

CREATININE, SERUM

18 - 60 yrs : 0.9 - 1.3 CREATININE 1.01 mg/dL

METHOD: JAFFE KINETIC METHOD

GLUCOSE, POST-PRANDIAL, PLASMA

Diabetes Mellitus : > or = 200. mg/dL GLUCOSE, POST-PRANDIAL, PLASMA 92

Impaired Glucose tolerance/ Prediabetes: 140 - 199. Hypoglycemia: < 55.

METHOD: HEXOKINASE

GLUCOSE FASTING, FLUORIDE PLASMA

GLUCOSE, FASTING, PLASMA 90 Diabetes Mellitus : > or = 126. mg/dL

Impaired fasting Glucose/ Prediabetes: 101 - 125. Hypoglycemia : < 55.

METHOD: HEXOKINASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

Normal : 4.0 - 5.6%. % 5.4 GLYCOSYLATED HEMOGLOBIN (HBA1C)

Non-diabetic level: < 5.7%. Diabetic : >6.5%

Glycemic control goal

More stringent goal : < 6.5 %. General goal : < 7%. Less stringent goal : < 8%.

Glycemic targets in CKD :-If eGFR > 60: < 7%. If eGFR < 60: 7 - 8.5%.

MEAN PLASMA GLUCOSE < 116.0 mg/dL 108.3

LIPID PROFILE, SERUM

Desirable: < 200 mg/dL 170 **CHOLESTEROL**

Borderline: 200-239 High : >or= 240

METHOD: CHOD-POD

TRIGLYCERIDES 142 Normal : < 150 mg/dL

High : 150-199

Hypertriglyceridemia: 200-499

Very High: > 499









PATIENT ID:

CLIENT PATIENT ID:

11/01/2023 17:18



VISWM1101924126

CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS :

REFERRING DOCTOR: DR. BANK OF BARODA

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI,

SOUTH DELHI 110030 DELHI INDIA 8800465156

DRAWN:

DDRC SRL DIAGNOSTICS

DDRC SRL Tower, G-131, Panampilly Nagar,

REPORTED:

PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. VISWESWARA PRABHU

ACCESSION NO: **4126WA003967** AGE: 31 Years SEX: Male ABHA NO:

RECEIVED: 11/01/2023 08:42

Test Report Status <u>Preliminary</u>	Results		Units
HDL CHOLESTEROL METHOD: DIRECT ENZYME CLEARANCE	51	General range : 40-60	mg/dL
DIRECT LDL CHOLESTEROL	115	Optimum : < 100 Above Optimum : 100-139 Borderline High : 130-159 High : 160-189 Very High : >or= 190	mg/dL
NON HDL CHOLESTEROL	119	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
CHOL/HDL RATIO	3.3	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	2.3	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate >6.0 High Risk	Risk
VERY LOW DENSITY LIPOPROTEIN	28.4	Desirable value : 10 - 35	mg/dL
LIVER FUNCTION TEST WITH GGT			
BILIRUBIN, TOTAL METHOD: DIAZO METHOD	0.45	General Range : < 1.1	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO METHOD	0.21	General Range : < 0.3	mg/dL
BILIRUBIN, INDIRECT	0.24	0.00 - 0.60	mg/dL
TOTAL PROTEIN	7.2	Ambulatory: 6.4 - 8.3 Recumbant: 6 - 7.8	g/dL
ALBUMIN	4.6	20-60yrs: 3.5 - 5.2	g/dL
GLOBULIN	2.6	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
ALBUMIN/GLOBULIN RATIO	1.8	1.00 - 2.00	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	14	Adults: < 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD: IFCC WITHOUT PDP	17	Adults : < 45	U/L
ALKALINE PHOSPHATASE METHOD: IFCC	58	Adult(<60yrs): 40 -130	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT)	12	Adult (Male): < 60	U/L









PATIENT ID:



VISWM1101924126

CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS :

PATIENT NAME: MR. VISWESWARA PRABHU

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

SOUTH DELHI, DELHI, SOUTH DELHI 110030 DELHI INDIA

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, F701A, LADO SARAI, NEW DELHI, PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in 8800465156

ACCESSION NO: **4126WA003967** AGE: 31 Years SEX: Male ABHA NO:

RECEIVED: 11/01/2023 08:42 11/01/2023 17:18 DRAWN: REPORTED:

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status <u>Preliminary</u>	Results		Units
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.2	Ambulatory: 6.4 - 8.3	g/dL
METHOD : BIURET		Recumbant : 6 - 7.8	
URIC ACID, SERUM			
URIC ACID	5.4	Adults: 3.4-7	mg/dL
METHOD : SPECTROPHOTOMETRY	_		
ABO GROUP & RH TYPE, EDTA WHOLE BLOO			
ABO GROUP METHOD: GEL CARD METHOD	В		
RH TYPE	POSITIVE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN METHOD: NON CYANMETHEMOGLOBIN	15.5	13.0 - 17.0	g/dL
RED BLOOD CELL COUNT METHOD: IMPEDANCE	5.24	4.5 - 5.5	mil/µL
WHITE BLOOD CELL COUNT METHOD: IMPEDANCE	6.73	4.0 - 10.0	thou/μL
PLATELET COUNT METHOD: IMPEDANCE	240	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT METHOD: CALCULATED	46.7	40 - 50	%
MEAN CORPUSCULAR VOL METHOD: DERIVED FROM IMPEDANCE MEASURE	89.1	83 - 101	fL
MEAN CORPUSCULAR HGB. METHOD: CALCULATED	29.5	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION METHOD: CALCULATED	33.1	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH	14.0	12.0 - 18.0	%
MENTZER INDEX	17.0		
MEAN PLATELET VOLUME METHOD: DERIVED FROM IMPEDANCE MEASURE	7.8	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
SEGMENTED NEUTROPHILS METHOD: DHSS FLOWCYTOMETRY	50	40 - 80	%
LYMPHOCYTES	38	20 - 40	%











VISWM1101924126

CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS :

ACCESSION NO: **4126WA003967** AGE: 31 Years

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI, SOUTH DELHI, DELHI,

SOUTH DELHI 110030 DELHI INDIA 8800465156

DDRC SRL DIAGNOSTICS

DDRC SRL Tower, G-131, Panampilly Nagar,

PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

ABHA NO:

PATIENT NAME: MR. VISWESWARA PRABHU PATIENT ID:

RECEIVED: 11/01/2023 08:42 11/01/2023 17:18 DRAWN: REPORTED:

SEX: Male

CLIENT PATIENT ID: REFERRING DOCTOR: DR. BANK OF BARODA

Tank Barrark Status - B. III i	DIL -		112
Test Report Status <u>Preliminary</u>	Results		Units
METHOD : DHSS FLOWCYTOMETRY			
MONOCYTES METHOD: DHSS FLOWCYTOMETRY	8	2 - 10	%
EOSINOPHILS METHOD: DHSS FLOWCYTOMETRY	4	1 - 6	%
BASOPHILS METHOD: IMPEDANCE	0	0 - 2	%
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED	3.36	2.0 - 7.0	thou/μL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED	2.56	1 - 3	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED	0.54	0.20 - 1.00	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED	0.27	0.02 - 0.50	thou/µL
ABSOLUTE BASOPHIL COUNT	0.00	0.00 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NI	•		
ERYTHROCYTE SEDIMENTATION RATE (ES BLOOD	R),WHOLE		
SEDIMENTATION RATE (ESR) METHOD: WESTERGREN METHOD	02	0 - 14	mm at 1 hr
* SUGAR URINE - POST PRANDIAL			
SUGAR URINE - POST PRANDIAL THYROID PANEL, SERUM	NOT DETECTED	NOT DETECTED	
T3 METHOD: ELECTROCHEMILUMINESCENCE	115.80	80 - 200	ng/dL
T4 METHOD: ELECTROCHEMILUMINESCENCE	8.83	5.1 - 14.1	μg/dl
TSH 3RD GENERATION METHOD: ELECTROCHEMILUMINESCENCE	2.490	21-50 yrs : 0.4 - 4.2	μIU/mL









PATIENT ID:



VISWM1101924126

CLIENT CODE: CA00010147 - MEDIWHEEL

CLIENT'S NAME AND ADDRESS : MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI, SOUTH DELHI 110030

DELHI INDIA 8800465156

ACCESSION NO:

DDRC SRL DIAGNOSTICS

DDRC SRL Tower, G-131, Panampilly Nagar,

PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

ABHA NO:

PATIENT NAME: MR. VISWESWARA PRABHU

4126WA003967 AGE:

RECEIVED: 11/01/2023 08:42 DRAWN: REPORTED: 11/01/2023 17:18

31 Years

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Results Units **Preliminary**

SEX: Male

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

4.8 - 7.4 PH 6.5 Low 1.015 - 1.030 SPECIFIC GRAVITY 1.010











CLIENT CODE: CA00010147 - MEDIWHEEL CLIENT'S NAME AND ADDRESS :

MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS

DDRC SRL Tower, G-131, Panampilly Nagar,

PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. VISWESWARA PRABHU

PATIENT ID: VISWM1101924126

ACCESSION NO: 4126WA003967 AGE: 31 Years SEX: Male ABHA NO:

RECEIVED: 11/01/2023 08:42 11/01/2023 17:18 DRAWN: REPORTED:

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status <u>Preliminary</u>	Results		Units
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
WBC	2-3	0-5	/HPF
EPITHELIAL CELLS	1-2	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	NOT DETECTED	NOT DETECTED	
YEAST	NOT DETECTED	NOT DETECTED	
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD: UREASE - UV	6	Adult(<60 yrs): 6 to 20	mg/dL
* SUGAR URINE - FASTING			
SUGAR URINE - FASTING	NOT DETECTED	NOT DETECTED	
* PHYSICAL EXAMINATION,STOOL	RESULT PENDING		
* CHEMICAL EXAMINATION,STOOL	RESULT PENDING		
* MICROSCOPIC EXAMINATION, STOOL	RESULT PENDING		

Interpretation(s)

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract

• Kidney problems, such as kidney damage or failure, infection, or reduced blood flow

Loss of body fluid (dehydration)Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

· Myasthenia Gravis

Muscular dystrophy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION









PATIENT ID:



VISWM1101924126

CLIENT CODE: CA00010147 - MEDIWHEEL

CLIENT'S NAME AND ADDRESS: MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036 KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. VISWESWARA PRABHU

4126WA003967 AGE: 31 Years SEX: Male ABHA NO: ACCESSION NO:

DRAWN: RECEIVED: 11/01/2023 08:42 REPORTED: 11/01/2023 17:18

REFERRING DOCTOR: DR. BANK OF BARODA CLIENT PATIENT ID:

Test Report Status Results Units **Preliminary**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus,

While failed hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods,falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

LIPID PROFILE, SERUM-Serum cholesterol is a blood test that can provide valuable information for the risk of coronary artery disease This test can help determine your risk of the build up of plaques in your arteries that can lead to narrowed or blocked arteries throughout your body (atherosclerosis). High cholesterol levels usually don""""""t cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn''''''t need into triglycerides, which are stored in fat settlin High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely.HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult.
TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum..Protein in the plasma is











CLIENT CODE: CA00010147 - MEDIWHEEL

CLIENT'S NAME AND ADDRESS: MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

REPORTED:

PATIENT NAME: MR. VISWESWARA PRABHU

PATIENT ID:

VISWM1101924126

4126WA003967 AGE: ACCESSION NO:

31 Years SEX: Male ABHA NO:

11/01/2023 17:18

DRAWN:

RECEIVED: 11/01/2023 08:42

CLIENT PATIENT ID:

REFERRING DOCTOR: DR. BANK OF BARODA **Test Report Status**

Preliminary

Results

Units

made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom"""'s disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging,

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

SUGAR URINE - POST PRANDIAL-METHOD: DIPSTICK/BENEDICT'S TEST

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.
SUGAR URINE - FASTING-METHOD: DIPSTICK/BENEDICT'S TEST



Page 9 Of 10 Scan to View Report







CLIENT CODE: CA00010147 - MEDIWHEEL

CLIENT'S NAME AND ADDRESS : MEDIWHEEL ARCOFEMI HEALTHCARE LIMITED

F701A, LADO SARAI, NEW DELHI,

SOUTH DELHI, DELHI, SOUTH DELHI 110030 **DELHI INDIA** 8800465156

DDRC SRL DIAGNOSTICS DDRC SRL Tower, G-131, Panampilly Nagar, PANAMPALLY NAGAR, 682036

KERALA, INDIA Tel: 93334 93334

Email: customercare.ddrc@srl.in

PATIENT NAME: MR. VISWESWARA PRABHU

REFERRING DOCTOR: DR. BANK OF BARODA

PATIENT ID:

VISWM1101924126

ACCESSION NO: 4126WA003967 AGE: 31 Years

SEX: Male

ABHA NO: REPORTED:

11/01/2023 17:18

DRAWN:

RECEIVED: 11/01/2023 08:42

CLIENT PATIENT ID:

Test Report Status

Preliminary

Results

Units

MEDIWHEEL HEALTH CHEKUP BELOW 40(M)TMT

* ECG WITH REPORT

RFPORT

TEST COMPLETED

* USG ABDOMEN AND PELVIS

REPORT

TEST COMPLETED

* CHEST X-RAY WITH REPORT

REPORT

TEST COMPLETED

End Of Report

Please visit www.srlworld.com for related Test Information for this accession TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

DR.HARI SHANKAR, MBBS MD **HEAD - Biochemistry &**

Immunology

DR.VIJAY K N,MD(PATH) **HEAD-HAEMATOLOGY & CLINICAL PATHOLOGY**


DR.SMITHA PAULSON, MD (PATH),DPB **LAB DIRECTOR & HEAD-**

HISTOPATHOLOGY & CYTOLOGY





Page 10 Of 10



Mains Filt: ON Amp: 10 mm Iso = R - 60 ms Post J = J + 60 ms $J = R + 60 \, ms$ Schiller Spandan V 4.7 Linked Median

Chart Speed: 25 mm/sec

Filter: 35 Hz



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 0 m 0 s Stage Time: 0 m 22 s HR: 86 bpm

Protocol: Bruce


Stage: Standing

Speed: 0 mph

Grade: 0 %

(THR: 160 bpm)

B.P: 110 / 70



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 2 m 54 s Stage Time: 2 m 54 s HR: 109 bpm


Protocol: Bruce

Stage: 1

Speed: 1.7 mph

Grade: 10 % (THR: 160 bpm)

B.P: 120 / 70



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time : 5 m 54 s Stage Time : 2 m 54 s HR: 133 bpm


Protocol: Bruce

Stage: 2

Speed: 2.5 mph Grade: 12 %

(THR: 160 bpm)

B.P: 130 / 70





Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 8 m 4 s Stage Time: 2 m 4 s HR: 167 bpm

Grade: 14 %


Protocol: Bruce

Stage: Peak Ex

Speed: 3.4 mph

(THR: 160 bpm)

B.P: 140 / 70



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 8 m 10 s Stage Time: 0 m 54 s HR: 120 bpm

Protocol: Bruce


Stage: Recovery(1)

Speed: 1 mph

Grade: 0 %

(THR: 160 bpm)

B.P: 170 / 70



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 8 m 10 s Stage Time: 0 m 54 s HR: 103 bpm

Protocol: Bruce


Stage: Recovery(2)

Speed: 0 mph

Grade: 0 %

(THR: 160 bpm)

B.P: 150 / 70



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 8 m 10 s Stage Time: 0 m 54 s HR: 106 bpm

Protocol: Bruce


Stage: Recovery(3)

Speed: 0 mph

Grade: 0 %

(THR: 160 bpm)

B.P: 130 / 70



Test Report

VISWESWARA PRABHU (31 M)

ID: WA003967

Date: 11-Jan-23

Exec Time: 8 m 10 s Stage Time: 0 m 54 s HR: 106 bpm


Protocol: Bruce

Stage: Recovery(4)

Speed: 0 mph

Grade: 0 % (THR: 160 bpm)

B.P: 130 / 70



Patient Details Date: 11-Jan-23 Time: 12:50:48

Name: VISWESWARA PRABHU ID: WA003967

Age: 31 y Sex: M Height: 178 cms. Weight: 83 Kg.

Clinical History: NIL

Medications: NIL

Test Details


Protocol: Bruce Pr.MHR: 189 bpm THR: 160 (85 % of Pr.MHR) bpm

Total Exec. Time: 8 m 10 s Max. HR: 166 (88% of Pr.MHR)bpm Max. Mets: 10.20

Test Termination Criteria: Target HR attained

Protocol Details

Stage Name	Stage Time	Mets	Speed	Grade	Heart	Max. BP	Max. ST	Max. ST
	(min : sec)		(mph)	(%)	Rate	(mm/Hg)	Level	Slope
					(bpm)		(mm)	(mV/s)
Supine	1:8	1.0	0	0	78	110 / 70	-0.64 aVR	1.42 V2
Standing	0:28	1.0	0	0	100	110 / 70	-0.64 aVR	1.42 V5
1	3:0	4.6	1.7	10	106	120 / 70	-0.85 aVR	2.12 V3
2	3:0	7.0	2.5	12	132	130 / 70	-0.85 aVR	3.54 V3
Peak Ex	2:10	10.2	3.4	14	166	140 / 70	-1.27 aVR	5.66 V3
Recovery(1)	1:0	1.8	1	0	126	170 / 70	-1.70 aVR	5.66 V4
Recovery(2)	1:0	1.0	0	0	109	150 / 70	-1.70 aVR	5.66 V5
Recovery(3)	1:0	1.0	0	0	108	130 / 70	-1.27 aVR	4.60 V3
Recovery(4)	0:8	1.0	0	0	118	120 / 70	-0.85 aVR	2.12



DI	ARC S	RL DIA	GNO	STIC S	ERVI	CE P	VT L	TD
-				UIIU U				

Patient Details Date: 11-Jan-23 Time: 12:50:48

Name: VISWESWARA PRABHU ID: WA003967

Age: 31 y Sex: M Height: 178 cms. Weight: 83 Kg.

Interpretation

The patient exercised according to the Bruce protocol for 8 m 10 s achieving a work level of Max. METS: 10.20. Resting heart rate initially 78 bpm, rose to a max. heart rate of 166 (88% of Pr.MHR) bpm. Resting blood Pressure 110 / 70 mmHg, rose to a maximum blood pressure of 170 / 70 mmHg, No Angina, No Arrhythmia.

- No Significan SI chenger - Test negative for induculate is chemic

Ref. Doctor: MEDIWHEEL

Doctor: ----

(Summary Report edited by user)





MEDICAL EXAMINATION REPORT (MER)

If the examinee is suffering from an acute life threatening situation, you may be obliged to disclose the result of the medical examination to the examinee.

1.	Name of the examinee	:	Mr./Mrs./Ms. Visweswana Prabhu
2.	Mark of Identification	Turker.	(Mole/Scar/any other (specify location)):
3.	Age/Date of Birth	:	07/06/1991 Gender: M · F/M
4.	Photo ID Checked	:	(Passport/Election Card/PAN Card/Driving Licence/Company ID)

PHYSICAL DETAILS:

a. Height	b. Weight (Kgs) e. Blood Pressure:	c. Girth of Abdomen	
	1 st Reading	of temperature to a first or a second residence of	
	2 nd Reading	organistic motores ministration for beset	

FAMILY HISTORY:

Relation	Age if Living	Health Status	If deceased, age at the time and cause
Father		1	
Mother			The state of the s
Brother(s)		142	
Sister(s)		Acons elgno all tit f	you think not the Ix MEDHOVELLY FIT or U.S.

HABITS & ADDICTIONS: Does the examinee consume any of the following?

Tobacco in any form	Sedative	Alcohol
or his-first identity and a first transport of	above nateodust after securication	Occasial

PERSONAL HISTORY

- a. Are you presently in good health and entirely free from any mental or Physical impairment or deformity.
 If No, please attach details.
- b. Have you undergone/been advised any surgical procedure?
- c. During the last 5 years have you been medically examined, received any advice or treatment or admitted to any hospital?
- d. Have you lost or gained weight in past 12 months?


Have you ever suffered from any of the following?

- Psychological Disorders or any kind of disorders of the Nervous System?
- Any disorders of Respiratory system?
- · Any Cardiac or Circulatory Disorders?
- Enlarged glands or any form of Cancer/Tumour?
- Any Musculoskeletal disorder?


- · Any disorder of Gastrointestinal System?
- Unexplained recurrent or persistent fever, and/or weight loss
- Have you been tested for HIV/HBsAg / HCV before? If yes attach reports
- Are you presently taking medication of any kind?







Any disorders of Offnary System?	IM	Mouth & Skin	YN
FOR FEMALE CANDIDATES ONLY	+		are Distrinsife St
a. Is there any history of diseases of breast/genital organs?		d. Do you have any history abortion or MTP	of miscarriage/
b. Is there any history of abnormal PAP Smear/Mammogram/USG of Pelvis or any othe tests? (If yes attach reports)	r Y/N	e. For Parous Women, were during pregnancy such a hypertension etc	
c. Do you suspect any disease of Uterus, Cervix or Ovaries?	Y/N	f. Are you now pregnant? I	If yes, how many months? Y/N
CONFIDENTAIL COMMENTS FROM MEDIC	CAL EXA	AMINER	(VA)
➤ Was the examinee co-operative?	1:05[1	- ang = all fight / d	Y/N
Is there anything about the examine's health, lift his/her job?	estyle th	at might affect him/her in the	near future with regard to Y/N
> Are there any points on which you suggest furth	her inform	mation be obtained?	Y/N
Based on your clinical impression, please provi	de your	suggestions and recommenda	tions below;
	014		
	NS		
Do you think he/she is MEDICALLY FIT or U	NEIT for	amployment	
Do you dillik lie/slie is MEDICALLI FIT of C	NFII IOI	employment.	
	F1.	acamera synthetica di escue	
MEDICAL EXAMINER'S DECLARATION			
I hereby confirm that I have examined the above indabove are true and correct to the best of my knowled		fter verification of his/her ide	entity and the findings stated
Name & Signature of the Medical Examiner :	6	Paragraphie in enginetiscon I	
		GEORGE THOMAS	
V/3X		MD. FCSI, FIME	
Seal of Medical Examiner :	5 / Y	DICAL EXAMINER	
	2		
N = 0 C - 1 CDDDC CDL D1		Samuel Develop	
Name & Seal of DDRC SRL Branch :		NGNOST	
		Soll Coll	infrared Later and Inch
Date & Time :	etell //	S (KADAVIL SULDINGS) 12	101/2023
Date & Time .		PANAMPILIY NASAR 5	Total the management
		1011	
	1	* ** *********************************	reall hardest-dustric graft









Viswerwara Picibhu Anjah . V

Motion test not arguised.

Jak .






Date. 11 . 01 - 2023

OPHTHALMOLOGY REPORT

This is to certif	y that I have examine	ed.	
Mr/Ms: Niswe	Swara Prabhu	Aged31and his / her	
visual standard	ls is as follows :		
Visual Acuity:	R: 616		
For far vision	L: 616		
For near vision	R:		
	L:		
Color Vision :	Normal	1/2/	AL REPLET NABAR
		Nannu Elizabeth (Optometrist)	PCHI-36





NAME: MR VISWESWARA PRABHU	STUDY DATE: 11/01/2023	
AGE / SEX :31 YRS / M	REPORTING DATE: 12/01/2023	
REFERRED BY : MEDIWHEEL	ACC NO: 4126WA003967	

X - RAY - CHEST PA VIEW

- > Both the lung fields are clear.
- B/L hila and mediastinal shadows are normal.
- Cardiac silhouette appears normal.
- Cardio thoracic ratio is normal.
- Bilateral CP angles and domes of diaphragm appear normal.

IMPRESSION: Normal study

Kindly correlate clinically

Dr. NAVNEET KAUR, MBBS,MD Consultant Radiologist.





NAME	MR VISWESWARA PRABHU			
	MIK VISWESWAKA PRABHU	AGE	31YRS	
SEX	MALE			
		DATE	January 11, 2023	
REFERRAL	MEDIWHEEL ARCOFEMI		Junuary 11, 2023	
*		ACC NO	4123WA003967	

USG ABDOMEN AND PELVIS

LIVER

Measures ~14.5cm. Normal in shape and normal echopattern.

Smooth margins and no obvious focal lesion within.

No IHBR dilatation.

Portal vein normal in caliber.

GB

No calculus within gall bladder. Normal GB wall caliber.

PANCREAS

Normal to visualized extent. PD is not dilated.

SPLEEN

Measures ~10.9 cm, normal to visualized extent. Splenic vein normal.

KIDNEYS

RK:10 x4.5 cm, normal in size and echotexture. LK: 10.2x 5.2cm, normal in size and echotexture.

No focal lesion / calculus within.

Maintained corticomedullary differentiation and normal parenchymal thickness.

No hydroureteronephrosis.

BLADDER

Normal wall caliber, no internal echoes/calculus within.

PROSTATE

Measures~24 cc, borderline prostatomegaly

NODES/FLUID

Nil to visualized extent.

BOWEL

Visualized bowel loops appear normal.

IMPRESSION

Borderline prostatomegaly.

No sonological detectable calculus in the kidneys.

Dr. JASICA JOY MD Consultant Radiologist

Thank you for referral. Your feedback will be appreciated.











